Arterial pharmacokinetics of red wine polyphenols: Implications for novel endovascular therapies targeting restenosis

Journal of Pharmaceutical Sciences

Volumn 101, Issue 5, 2012, Pages 1917-1931

  Kleinedler, James J ^a   Pjescic, Ilija ^b   Bullock, Kirby K ^a   Khaliq, Abdul ^b   Foley, John D ^c   Dugas, Tammy R ^a  

^a LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b LOUISIANA TECH UNIVERSITY   (United States)

^c ReQuisite Biomedical   (United States)

Author keywords

Arterial kinetics; Artery; Diffusion; Mathematical model; Natural products; Physicochemical; Polymeric drug carrier; Stent

Indexed keywords

PACLITAXEL; QUERCETIN; RESVERATROL; POLYPHENOL;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG ELUTING STENT; DRUG RELEASE; DRUG RETENTION; DRUG SAFETY; DRUG TRANSPORT; NONHUMAN; PROTEIN BINDING; RAT; RED WINE; RESTENOSIS; TISSUE DISTRIBUTION; ANIMAL; ARTERY; CATTLE; GRAFT OCCLUSION; METABOLISM; WINE;

ANIMALS; ARTERIES; CATTLE; GRAFT OCCLUSION, VASCULAR; PACLITAXEL; POLYPHENOLS; WINE;

EID: 84864296345     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23074     Document Type: Article

References (48)

1. Babapulle MN, Eisenberg MJ. 2002. Coated stents for the prevention of restenosis: Part I. Circulation 106(21):2734-2740.
2. Finn AV, Kolodgie FD, Harnek J, Guerrero LJ, Acampado E, Tefera K, Skorija K, Weber DK, Gold HK, Virmani R. 2005. Differential response of delayed healing and persistent inflammation at sites of overlapping sirolimus- or paclitaxel-eluting stents. Circulation 112(2):270-278.
3. van den Heuvel M, Sorop O, van Beusekom HM, van der Giessen WJ. 2009. Endothelial dysfunction after drug eluting stent implantation. Minerva Cardioangiol 57(5):629-643.
4. Lovich MA, Creel C, Hong K, Hwang CW, Edelman ER. 2001. Carrier proteins determine local pharmacokinetics and arterial distribution of paclitaxel. J Pharm Sci 90(9):1324-1335.
5. Lovich MA, Philbrook M, Sawyer S, Weselcouch E, Edelman ER. 1998. Arterial heparin deposition: Role of diffusion, convection, and extravascular space. Am J Physiol 275(6 Pt 2):H2236-H2242.
6. Serruys PW, Emanuelsson H, van der Giessen W, Lunn AC, Kiemeney F, Macaya C, Rutsch W, Heyndrickx G, Suryapranata H, Legrand V, Goy JJ, Materne P, Bonnier H, Morice MC, Fajadet J, Belardi J, Colombo A, Garcia E, Ruygrok P, de Jaegere P, Morel MA. 1996. Heparin-coated Palmaz-Schatz stents in human coronary arteries. Early outcome of the Benestent-II Pilot Study. Circulation 93(3):412-422.
7. Park SH, Lincoff AM. 1998. Anti-inflammatory stent coatings: Dexamethasone and related compounds. Semin Interv Cardiol 3(3-4):191-195.
8. Colombo A, Drzewiecki J, Banning A, Grube E, Hauptmann K, Silber S, Dudek D, Fort S, Schiele F, Zmudka K, Guagliumi G, Russell ME. 2003. Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation 108(7):788-794.
9. Sousa JE, Costa MA, Abizaid A, Abizaid AS, Feres F, Pinto IM, Seixas AC, Staico R, Mattos LA, Sousa AG, Falotico R, Jaeger J, Popma JJ, Serruys PW. 2001. Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: A quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation 103(2):192-195.
10. Ekshyyan VP, Hebert VY, Khandelwal A, Dugas TR. 2007. Resveratrol inhibits rat aortic vascular smooth muscle cell proliferation via estrogen receptor dependent nitric oxide production. J Cardiovasc Pharmacol 50(1):83-93.
11. J G, Cq W, Hh F, Hy D, Xl X, Ym X, By W, Dj H. 2006. Effects of resveratrol on endothelial progenitor cells and their contributions to reendothelialization in intima-injured rats. J Cardiovasc Pharmacol 47(5):711-721.
12. Csiszar A, Smith K, Labinskyy N, Orosz Z, Rivera A, Ungvari Z. 2006. Resveratrol attenuates TNF-alpha-induced activation of coronary arterial endothelial cells: Role of NF-kappaB inhibition. Am J Physiol Heart Circ Physiol 291(4):H1694-H1699.
13. Kleinedler JJ, Foley JD, Alexander JS, Hebert VY, Dugas TR. 2011. Synergistic effect of resveratrol and quercetin released from drug-eluting polymer coatings for endovascular devices. J Biomed Mater Res B Appl Biomater 99(2):266-275.
14. Pinchuk L, Wilson GJ, Barry JJ, Schoephoerster RT, Parel JM, Kennedy JP. 2008. Medical applications of poly(styrene-block-isobutylene-block-styrene) ("SIBS"). Biomaterials 29(4):448-460.
15. Puskas J. 2005. Synthesis and characterization of novel dendritic (arborescent, hyperbranched) polyisobutylene-polystyrene block copolymers. J Polym Sci A Polym Chem 43(9):1811-1826.
16. Sakharov DV, Kalachev LV, Rijken DC. 2002. Numerical simulation of local pharmacokinetics of a drug after intravascular delivery with an eluting stent. J Drug Target 10(6):507-513.
17. Dow N. 2002. Determination of compound binding to plasma proteins. Curr Protoc 12(18):7.5.1-7.5.14.
18. Creel CJ, Lovich MA, Edelman ER. 2000. Arterial paclitaxel distribution and deposition. Circ Res 86(8):879-884.
19. Bock J. 1949. Serum protein concentration and relative albumin percentage in normal individuals. Acta Physiol Scand 18(2-3):231-237.
20. Levin AD, Vukmirovic N, Hwang CW, Edelman ER. 2004. Specific binding to intracellular proteins determines arterial transport properties for rapamycin and paclitaxel. Proc Natl Acad Sci U S A 101(25):9463-9467.
21. Hwang CW, Wu D, Edelman ER. 2001. Physiological transport forces govern drug distribution for stent-based delivery. Circulation 104(5):600-605.
22. Hwang CW, Edelman ER. 2002. Arterial ultrastructure influences transport of locally delivered drugs. Circ Res 90(7):826-832.
23. Bratzler RL, Chisolm GM, Colton CK, Smith KA, Zilversmit DB, Lees RS. 1977. The distribution of labeled albumin across the rabbit thoracic aorta in vivo. Circ Res 40(2):182-190.
24. Crank J. 1979. The mathematics of diffusion. 2nd ed. Oxford: Clarendon Press.
25. Chen DR, Pui DYH, Kaufman SL. 1995. Electrospraying of conducting liquids for monodisperse aerosol generation in the 4 nm to 1.8 μm diameter range. J Aerosol Sci 26:14.
26. van der Woude H, Gliszczynska-Swiglo A, Struijs K, Smeets A, Alink GM, Rietjens IM. 2003. Biphasic modulation of cell proliferation by quercetin at concentrations physiologically relevant in humans. Cancer Lett 200(1):41-47.
27. Balakrishnan B, Dooley J, Kopia G, Edelman ER. 2008. Thrombus causes fluctuations in arterial drug delivery from intravascular stents. J Control Release 131(3):173-180.
28. Siepmann J, Peppas NA. 2001. Mathematical modeling of controlled drug delivery. Adv Drug Deliv Rev 48(2-3):137-138.
29. Hose DR, Narracott AJ, Griffiths B, Mahmood S, Gunn J, Sweeney D, Lawford PV. 2004. A thermal analogy for modelling drug elution from cardiovascular stents. Comput Methods Biomech Biomed Eng 7(5):257-264.
30. Zunino P. 2004. Multidimensional pharmacokinetic models applied to the design of drug-eluting stents. Cardiov Eng 4(2):181-191.
31. Ali ZA, Alp NJ, Lupton H, Arnold N, Bannister T, Hu Y, Mussa S, Wheatcroft M, Greaves DR, Gunn J, Channon KM. 2007. Increased in-stent stenosis in ApoE knockout mice: Insights from a novel mouse model of balloon angioplasty and stenting. Arterioscler Thromb Vasc Biol 27(4):833-840.
32. Pan CJ, Tang JJ, Weng YJ, Wang J, Huang N. 2009. Preparation and in vitro release profiles of drug-eluting controlled biodegradable polymer coating stents. Colloids Surf B Biointerfaces 73(2):199-206.
33. Kamath KR, Barry JJ, Miller KM. 2006. The Taxus drug-eluting stent: A new paradigm in controlled drug delivery. Adv Drug Deliv Rev 58(3):412-436.
34. Dong J, Foley JD, Frethem CD, Hoerr RA, Matuszewski MJ, Puskas JE, Haugstad G. 2009. Multimodal dynamic imaging of therapeutic biomedical coatings in aqueous medium. Langmuir 25(10):5442-5445.
35. Kumar GN, Walle UK, Bhalla KN, Walle T. 1993. Binding of taxol to human plasma, albumin and alpha 1-acid glycoprotein. Res Commun Chem Pathol Pharmacol 80(3):337-344.
36. Balakrishnan B, Dooley J, Kopia G, Edelman ER. 2007. Intravascular drug release kinetics dictate arterial drug deposition, retention, and distribution. J Control Release 123(2):100-108.
37. Radeleff B, Thierjung H, Stampfl U, Stampfl S, Lopez-Benitez R, Sommer C, Berger I, Richter GM. 2008. Restenosis of the CYPHER-Select, TAXUS-Express, and Polyzene-F nanocoated cobalt-chromium stents in the minipig coronary artery model. Cardiovasc Intervent Radiol 31(5):971-980.
38. Joner M, Nakazawa G, Finn AV, Quee SC, Coleman L, Acampado E, Wilson PS, Skorija K, Cheng Q, Xu X, Gold HK, Kolodgie FD, Virmani R. 2008. Endothelial cell recovery between comparator polymer-based drug-eluting stents. J Am Coll Cardiol 52(5):333-342.
39. Venkatraman S, Boey F. 2007. Release profiles in drug-eluting stents: Issues and uncertainties. J Control Release 120(3):149-160.
40. Finn AV, Nakazawa G, Joner M, Kolodgie FD, Mont EK, Gold HK, Virmani R. 2007. Vascular responses to drug eluting stents: Importance of delayed healing. Arterioscler Thromb Vasc Biol 27(7):1500-1510.
41. Zou J, Huang Y, Cao K, Yang G, Yin H, Len J, Hsieh TC, Wu JM. 2000. Effect of resveratrol on intimal hyperplasia after endothelial denudation in an experimental rabbit model. Life Sci 68(2):153-163.
42. Huang BF, Wang W, Fu YC, Zhou XH, Wang X. 2009. The effect of quercetin on neointima formation in a rat artery balloon injury model. Pathol Res Pract 205(8):515-523.
43. Khandelwal AR, Hebert VY, Dugas TR. Essential role of ER-alpha-dependent NO production in resveratrol-mediated inhibition of restenosis. Am J Physiol Heart Circ Physiol 299(5):H1451-H1458.
44. Sirianni RW, Kremer J, Guler I, Chen YL, Keeley FW, Saltzman WM. 2008. Effect of extracellular matrix elements on the transport of paclitaxel through an arterial wall tissue mimic. Biomacromolecules 9(10):2792-2798.
45. Goriely AR, Baldwin AL, Secomb TW. 2007. Transient diffusion of albumin in aortic walls: Effects of binding to medial elastin layers. Am J Physiol Heart Circ Physiol 292(5):H2195-H2201.
46. Tzafriri AR, Vukmirovic N, Kolachalama VB, Astafieva I, Edelman ER. 2010. Lesion complexity determines arterial drug distribution after local drug delivery. J Control Release 142(3):332-338.
47. Hezi-Yamit A, Sullivan C, Wong J, David L, Chen M, Cheng P, Shumaker D, Wilcox JN, Udipi K. 2009. Impact of polymer hydrophilicity on biocompatibility: Implication for DES polymer design. J Biomed Mater Res A 90(1):133-141.
48. Lovich MA, Edelman ER. 1995. Mechanisms of transmural heparin transport in the rat abdominal aorta after local vascular delivery. Circ Res 77(6):1143-1150.